医学
化疗
肿瘤科
卵巢癌
内科学
上皮性卵巢癌
疾病
阶段(地层学)
人口
生活质量(医疗保健)
癌症
古生物学
护理部
环境卫生
生物
作者
Nilanchali Singh,Aarthi S Jayraj,Avir Sarkar,Trishala Mohan,Amlin Shukla,Prafull Ghatage
标识
DOI:10.1080/14656566.2022.2112030
摘要
INTRODUCTION: Almost 80% of epithelial ovarian cancer present in advanced stage at diagnosis and despite excellent response to surgery and chemotherapy, more than 70% cancers recur. Subsequent therapies become decreasingly effective in controlling the disease, with each successful therapy being effective for a shorter duration. As a result, there is a need for novel therapeutic strategies to effectively treat recurrence. AREAS COVERED: In this extensive literature review of high-quality articles, we have focused on surveillance strategy to detect recurrence early, classification of recurrence based on timeline, role of surgery, chemotherapy, and targeted agents such as anti-angiogenetic drugs, PARP inhibitors, and immune checkpoint inhibitors in platinum-sensitive and platinum-resistant disease, respectively. EXPERT OPINION: Recurrent ovarian cancers (ROC) are represented by a heterogenous group of patient population in terms of platinum-free interval (PFI), histology, molecular characteristics and immune recognition. In today's era of precision medicine, chemotherapy should be combined with appropriate targeted agent in a multipronged approach to prolong survival and provide better quality of life outcomes by minimizing side effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI